Observations placeholder

Lacosamide (INN, formerly known as erlosamide, harkeroside, SPM 927, or ADD 234037) for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain marketed under the trade name Vimpat.

Side-effects

The side-effects most commonly leading to discontinuation were dizziness, ataxia, vomiting, diplopia (double vision), nausea, vertigo, and blurred vision. These adverse reactions were observed in at least 10% of patients. Less common side-effects include forgetfulness, discouragement, feelings of sadness, and lack of appetite.

Gastrointestinal

Nausea, vomiting, diarrhea.

Central Nervous system

Dizziness was the most common treatment-related adverse event. Other CNS effects are headache, drowsiness, blurred vision, involuntary movements, weakness, tiredness, memory problems, diplopia, trembling or shaking of the hands, unsteadiness, ataxia.

Psychology

Panic attacks; agitation or restlessness; irritability and aggression, anxiety, or depression; suicidality; insomnia and mania; altered mood; false and unusual sense of well-being.

Cardiovascular

Postural hypotension, arrhythmias.

Allergies

Itching, rash, pruritus

Warnings

Suicidal behavior and ideation have been observed as early as one week after starting treatment with lacosamide, and is an adverse reaction from use of most AEDs.  Suicidal behavior was observed in 1 of every 530 patients treated.

In Pregnancy

In a study conducted to assess the teratogenic potential of AEDs in the zebrafish embryo, the teratogenicity index of lacosamide was found to be higher than that of lamotigrine, levetiracetam, and ethosuximide. Lacosamide administration resulted in different malformations in the neonatal zebrafish depending on dosage.

The FDA has assigned lacosamide to pregnancy category C. Animal studies have reported incidences of fetal mortality and growth deficit. Lacosamide has not been tested during human pregnancy. In addition, it has not been determined whether the excretion of lacosamide occurs in breast milk

Time on Vimpat when people have Hallucination  :

Gender of people who have Hallucination when taking Vimpat  :

Age of people who have Hallucination when taking Vimpat  :

On Feb, 14, 2016: 1,929 people reported to have side effects when taking Vimpat. Among them, 66 people (3.42%) have Death.

Time on Vimpat when people have Death  :

Gender of people who have Death when taking Vimpat  :

Age of people who have Death when taking Vimpat  :

Top conditions involved for these people  :

1. Epilepsy (27 people, 40.91%)
2. Partial seizures (5 people, 7.58%)
3. Convulsion (5 people, 7.58%)
4. Complex partial seizures (2 people, 3.03%)